Nascent Biotech, Inc. (NBIO)

Nascent Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	-	-	-	1	0.75	-
Revenue Growth (YoY)	-	-	-	33.33%	-	-
Cost of Revenue	0.3	0.32	-	-	-	-
Gross Profit	-0.3	-0.32	-	1	0.75	-
Selling, General & Admin	1.63	1.71	1.5	0.93	1.83	3.15
Research & Development	0.16	0.2	0.65	0.53	0.32	0.29
Operating Expenses	1.8	1.91	2.16	1.46	2.15	3.45
Operating Income	-2.09	-2.23	-2.16	-0.46	-1.4	-3.45
Interest Expense	-0.15	-0.39	-1.72	-0.34	-0.34	-0.09
Interest & Investment Income	0.01	0.01	0	0	0	0
Other Non Operating Income (Expenses)	0.31	0.47	1.05	0.32	0.63	-0.47
EBT Excluding Unusual Items	-1.92	-2.14	-2.83	-0.48	-1.11	-4
Other Unusual Items	-	0.05	0.03	0.01	0.15	-
Pretax Income	-1.92	-2.09	-2.8	-0.47	-0.96	-4
Net Income	-1.92	-2.09	-2.8	-0.47	-0.96	-4
Net Income to Common	-1.92	-2.09	-2.8	-0.47	-0.96	-4
Shares Outstanding (Basic)	163	156	119	108	72	34
Shares Outstanding (Diluted)	163	156	119	108	72	34
Shares Change (YoY)	30.53%	31.35%	10.05%	48.93%	110.34%	14.30%
EPS (Basic)	-0.01	-0.01	-0.02	-0.00	-0.01	-0.12
EPS (Diluted)	-0.01	-0.01	-0.02	-0.00	-0.01	-0.12
Free Cash Flow	-1.35	-1.19	-1.79	0.41	-0.99	-0.55
Free Cash Flow Per Share	-0.01	-0.01	-0.02	0.00	-0.01	-0.02
Gross Margin	-	-	-	100.00%	100.00%	-
Operating Margin	-	-	-	-45.71%	-186.72%	-
Profit Margin	-	-	-	-47.04%	-127.84%	-
Free Cash Flow Margin	-	-	-	41.35%	-131.57%	-
EBIT	-2.09	-2.23	-2.16	-0.46	-1.4	-3.45
EBIT Margin	-	-	-	-45.71%	-186.72%	-

Source: S&P Capital IQ. Standard template. Financial Sources.